An Open-Label Study of the Treatment Efficacy of Olanzapine for Tourette's Disorder
The DOI matches its Crossref record.
Abstract
BACKGROUND: An open-label trial was performed to explore efficacy and safety of olanzapine, an atypical neuroleptic with diverse receptor activity including both dopamine-2 and serotonin-2A and -2C antagonism, for treatment of Tourette's disorder. METHOD: Ten adult patients aged 20 to 44 years with Tourette's disorder were treated using an open-label, flexible dosing schedule for 8 weeks. Three patients who continued olanzapine were reevaluated after 6 months. Three subjects were psychotropic medication naive, 5 patients experienced intolerable side effects with conventional neuroleptics, and 2 patients had remote (> or = 10 years) successful response to conventional neuroleptics. Tic severity was rated by the Yale Global Tic Severity Scale; weight, vital signs, and adverse effects were assessed weekly. Electrocardiogram, laboratory studies, and comorbid symptoms, assessed by the Yale-Brown Obsessive Compulsive Scale and ADHD Behavior Checklist for Adults, were measured at baseline and at week 8. RESULTS: Two of 10 patients prematurely discontinued olanzapine owing to excessive sedation. Of 8 patients who completed the 8-week trial, 4 (50%) demonstrated reduction of global tic severity scores by > or = 20 points, and 6 (75%) demonstrated reductions by > or = 10 points. No significant changes in comorbid symptoms were demonstrated. Sedation, weight gain, increased appetite, dry mouth, and transient asymptomatic hypoglycemia were the most common side effects. Tic improvements were maintained in 3 patients reassessed 6 months later. Final olanzapine dosages ranged from 2.5 mg to 20 mg daily (mean = 10.9 mg/day). CONCLUSION: This open-label study suggests that olanzapine should be explored as a potential alternative to conventional neuroleptic medications for treatment of motor tics and Tourette's disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Leckman, J. F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11526-1 · Cited by 685
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
the ESSTS Guidelines Group, Roessner, V., Plessen, K. J., Rothenberger, A., Ludolph, A. G., Rizzo, R., Skov, L., Strand, G., Stern, J. S., Termine, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0163-7 · Cited by 461
Wolff, A., Joshi, R. K., Ekström, J., Aframian, D., Pedersen, A. M. L., Proctor, G., Narayana, N., Villa, A., Sia, Y. W., Aliko, A., et al. (2017) · Drugs in R&D · doi:10.1007/s40268-016-0153-9 · Cited by 364
A placebo-controlled trial of risperidone in Tourette syndrome
Scahill, L., Leckman, J. F., Schultz, R. T., Katsovich, L., & Peterson, B. S. (2003) · Neurology · doi:10.1212/01.wnl.0000055434.39968.67 · Cited by 362
Metadata
- Authors
- Budman, C. L., Gayer, A., Lesser, M., Shi, Q., & Bruun, R. D.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2001-04-15
- Volume
- 62
- Issue
- 4
- Pages
- 290-294
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1978345770
- Cited by
- 111
- References
- 0
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Open-Label Study of the Treatment Efficacy of Olanzapine for Tourette's Disorder. https://app.cochat.ai/papers/10.4088/jcp.v62n0412
- The paper
- Budman, C. L., Gayer, A., Lesser, M., Shi, Q., & Bruun, R. D. (2001). An Open-Label Study of the Treatment Efficacy of Olanzapine for Tourette's Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v62n0412
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.